SCHEMBL12869593

SCHEMBL12869593

OC(c1ccc(F)cc1)c1ccccc1C(F)(F)Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
KMT2A Q03164 2/20 0.35
ATM Q13315 2/20 0.35
KCNN4 O15554 3/20 0.35
ADORA2A P29274 2/20 0.35
ADORA1 P30542 1/20 0.35
ACP3 P15309 1/20 0.34
TOP2A P11388 2/20 0.33
TOP2B Q02880 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
KCNE1 P15382 1/20 0.33
KCNQ1 P51787 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083661 0.88 ACP3 (0.45) CYP11B1CYP11B2KMT2AATMKCNN4
SCHEMBL12869580 0.87 ADORA2A (0.44) CYP11B1CYP11B2KMT2AADORA2AADORA1
SCHEMBL11862016 0.77 CYP11B1 (0.39) CYP11B1CYP11B2KMT2AATMMEN1
SCHEMBL30986699 0.77 CYP11B1 (0.39) CYP11B1CYP11B2KMT2AATMMEN1
SCHEMBL30910920 0.77 CYP11B1 (0.39) CYP11B1CYP11B2KMT2AATMMEN1
SCHEMBL30986702 0.76 CES2 (0.43) CYP11B1CYP11B2KMT2AATMKCNN4
SCHEMBL6566037 0.76 CES2 (0.43) CYP11B1CYP11B2KMT2AATMKCNN4
SCHEMBL30910940 0.76 CES2 (0.43) CYP11B1CYP11B2KMT2AATMKCNN4
SCHEMBL23003634 0.74 GABRA1 (0.43) CYP11B1CYP11B2KMT2AATMTOP2A
SCHEMBL3294921 0.74 ACP3 (0.57) KMT2AADORA2AADORA1ACP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280983-B9 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM (FR) 2021-06-09 EP disclosed
US-8486897-B2 C-aryl glycoside compounds for the treatment of diabetes and obesity TFCHEM (FR) 2013-07-16 US disclosed
US-8486897-B2 C-aryl glycoside compounds for the treatment of diabetes and obesity TFCHEM (FR) 2013-07-16 US disclosed
EP-2280983-B1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM (FR) 2013-03-13 EP disclosed
US-20110034402-A1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034402-A1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY SLC5A2, SLC5A1, GPR119 CYP11B1 51/4885CYP11B2 76/4885KMT2A 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.